Macular Degeneration News and Research RSS Feed - Macular Degeneration News and Research

Macular degeneration is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving.
Researchers compare effectiveness of two stem cell types in treating retinal degeneration

Researchers compare effectiveness of two stem cell types in treating retinal degeneration

By growing two types of stem cells in a "3-D culture" and measuring their ability to produce retinal cells, a team lead by St. Jude Children's Research Hospital researchers has found one cell type to be better at producing retinal cells. [More]
OCT angiography shows promise in CNV detection

OCT angiography shows promise in CNV detection

Noninvasive optical coherence tomography angiography can successfully detect choroidal neovascularisation, research findings indicate. [More]

Polypoidal choroidal vasculopathy shows distinct classification

Researchers have found that idiopathic polypoidal choroidal vasculopathy has significant clinical differences to neovascular age-related macular degeneration and suggest that it should be considered a distinct entity. [More]

RPE transdifferentiation revealed in AMD

Subducted and melanotic cells in the eyes of patients with advanced age-related macular degeneration derive from two distinct retinal pigment epithelium phenotypes, research shows. [More]

ORT incidence increases in nAMD despite anti-VEGF treatment

Swiss researchers report that patients with neovascular age-related macular degeneration (nAMD) experience increased incidence of outer retinal tubulation over time, despite treatment with a vascular endothelial growth factor blocker. [More]
Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for eyes -- the replacement of a faulty gene with a healthy one -- is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people with a genetic disorder that leaves them blind by middle age. [More]
iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics, today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. [More]
UAB optometrist offers tips to keep eyes healthy during summer months

UAB optometrist offers tips to keep eyes healthy during summer months

While the warm summer months are perfect for spending time outside, several environmental factors can spell trouble for eyesight. One University of Alabama at Birmingham optometrist says knowledge of what to do, and what not to do, will keep eyes healthy. [More]
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]
Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. [More]
Oraya IRay Radiotherapy System for AMD treatment receives Silver award at MDEA 2015

Oraya IRay Radiotherapy System for AMD treatment receives Silver award at MDEA 2015

Oraya Therapeutics Inc.and Bridge Design announced today that the Oraya IRay Radiotherapy System has won the Silver award in the radiological and electromechanical devices category of the 18 Annual Medical Design Excellence Awards (MDEA).The winners were announced at a ceremony in New York City at the Jacob Javits Center in conjunction with the MD&M East event. [More]
OphthaliX enters into definitive agreement to purchase Improved Vision Systems

OphthaliX enters into definitive agreement to purchase Improved Vision Systems

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today it has signed a definitive agreement to acquire Israel-based Improved Vision Systems Ltd. in a stock-for-stock transaction. [More]

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. [More]
New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

New York Eye and Ear Infirmary of Mount Sinai observes June 1st as World Orthoptics Day

New York Eye and Ear Infirmary of Mount Sinai joins with the International Orthoptic Association to observe June 1st as World Orthoptics Day. [More]
Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

The Centers for Medicare & Medicaid Services today released to the public data relating to 2013 Medicare payments made to physicians and other providers. In response, the American Academy of Ophthalmology is providing necessary context for the reimbursement data, which in its raw form are often complex and difficult to understand. [More]
Researchers identify previously unknown gene mutation that causes achromatopsia

Researchers identify previously unknown gene mutation that causes achromatopsia

People with achromatopsia, an inherited eye disorder, see the world literally in black and white. Worse yet, their extreme sensitivity to light makes them nearly blind in bright sunlight. Now, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health System have identified a previously unknown gene mutation that underlies this disorder. [More]
Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

People with achromatopsia, an inherited eye disorder, see the world literally in black and white. Worse yet, their extreme sensitivity to light makes them nearly blind in bright sunlight. Now, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health System have identified a previously unknown gene mutation that underlies this disorder. [More]
Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the three months ended March 31, 2015 and updates on its drug development programs. [More]
Metformin can reduce risk of open-angle glaucoma in people with diabetes

Metformin can reduce risk of open-angle glaucoma in people with diabetes

Taking the medication metformin hydrochloride was associated with reduced risk of developing the sight-threatening disease open-angle glaucoma in people with diabetes, according to a study published online by JAMA Ophthalmology. [More]

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
Advertisement
Advertisement